Objective To study the value of autotaxin (an autocrine motility factor) level in serum and bronchoalveolar lavage fluid (BALF) in predicting refractory Mycoplasma pneumoniae pneumonia (RMPP) in children and its correlation with interleukin-6 (IL-6), interleukin-8 (IL-8), and C-reactive protein (CRP). Methods A retrospective analysis was performed on 238 children with Mycoplasma pneumoniae pneumonia who were admitted from January 2019 to December 2021. According to disease severity, they were divided into two groups: RMPP (n=82) and general Mycoplasma pneumoniae pneumonia (GMPP; n=156). The two groups were compared in terms of the levels of autotaxin, IL-6, IL-8, and CRP in serum and BALF to study the value of autotaxin level in serum and BALF in predicting RMPP in children, as well as the correlation of autotaxin level with IL-6, IL-8, and CRP in children with RMPP. Results Compared with the GMPP group, the RMPP group had significantly higher levels of autotaxin, IL-6, IL-8, and CRP in serum and BALF (P<0.05). For the children with RMPP, the levels of autotaxin, IL-6, IL-8, and CRP in serum and BALF in the acute stage were significantly higher than those in the convalescent stage (P<0.05). The receiver operating characteristic (ROC) curve showed that the level of autotaxin in serum and BALF had a good value in predicting RMPP in children, with an area under the curve of 0.874 (95%CI: 0.816-0.935) and 0.862 (95%CI: 0.802-0.924), respectively. The correlation analysis showed that the level of autotaxin in serum and BALF was positively correlated with IL-6, IL-8, and CRP levels (P<0.001). Conclusions The level of autotaxin in serum and BALF increases and is correlated with the degree of disease recovery and inflammatory cytokines in children with RMPP. Autotaxin can be used as a predictive indicator for RMPP in children.
Key words
Refractory Mycoplasma pneumoniae pneumonia /
Autocrine motility factor /
Inflammatory cytokine /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Esposito S, Argentiero A, Gramegna A, et al. Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems[J]. Expert Opin Pharmacother, 2021, 22(9): 1193-1202. PMID: 33544008. DOI: 10.1080/14656566.2021.1882420.
2 Cho HK. Consideration in treatment decisions for refractory Mycoplasma pneumoniae pneumonia[J]. Clin Exp Pediatr, 2021, 64(9): 459-467. PMID: 33561337. PMCID: PMC8426095. DOI: 10.3345/cep.2020.01305.
3 贺宇杉, 杨梅, 钱素云. 细胞因子对难治性肺炎支原体肺炎的预测作用[J]. 中华儿科杂志, 2021, 59(5): 422-425. PMID: 33902231. DOI: 10.3760/cma.j.cn112140-20201125-01056.
4 Chen P, Huang Z, Chen L, et al. The relationships between LncRNA NNT-AS1, CRP, PCT and their interactions and the refractory Mycoplasma pneumoniae pneumonia in children[J]. Sci Rep, 2021, 11(1): 2059. PMID: 33479472. PMCID: PMC7820231. DOI: 10.1038/s41598-021-81853-w.
5 Nikitopoulou I, Fanidis D, Ntatsoulis K, et al. Increased autotaxin levels in severe COVID-19, correlating with IL-6 levels, endothelial dysfunction biomarkers, and impaired functions of dendritic cells[J]. Int J Mol Sci, 2021, 22(18): 10006. PMID: 34576169. PMCID: PMC8469279. DOI: 10.3390/ijms221810006.
6 中华医学会儿科学分会呼吸学组, 《中华实用儿科临床杂志》编辑委员会. 儿童肺炎支原体肺炎诊治专家共识(2015年版)[J]. 中华实用儿科临床杂志, 2015, 30(17): 1304-1308. DOI: 10.3760/cma.j.issn.2095-428X.2015.17.006.
7 Rogozinski LE, Alverson BK, Biondi EA. Diagnosis and treatment of Mycoplasma pneumoniae in children[J]. Minerva Pediatr, 2017, 69(2): 156-160. PMID: 28178776. DOI: 10.23736/S0026-4946.16.04866-0.
8 Lee E, Lee YY. Predictive factors of the responses to treatment of Mycoplasma pneumoniae pneumonia[J]. J Clin Med, 2021, 10(6): 1154. PMID: 33801856. PMCID: PMC7998824. DOI: 10.3390/jcm10061154.
9 Lin S, Haque A, Raeman R, et al. Autotaxin determines colitis severity in mice and is secreted by B cells in the colon[J]. FASEB J, 2019, 33(3): 3623-3635. PMID: 30481488. PMCID: PMC6404565. DOI: 10.1096/fj.201801415RR.
10 Nikitopoulou I, Ninou I, Manitsopoulos N, et al. A role for bronchial epithelial autotaxin in ventilator-induced lung injury[J]. Intensive Care Med Exp, 2021, 9(1): 12. PMID: 33778909. PMCID: PMC8005331. DOI: 10.1186/s40635-021-00379-7.
11 Gao L, Li X, Wang H, et al. Autotaxin levels in serum and bronchoalveolar lavage fluid are associated with inflammatory and fibrotic biomarkers and the clinical outcome in patients with acute respiratory distress syndrome[J]. J Intensive Care, 2021, 9(1): 44. PMID: 34130757. PMCID: PMC8207767. DOI: 10.1186/s40560-021-00559-3.
12 Gong H, Sun B, Chen Y, et al. The risk factors of children acquiring refractory Mycoplasma pneumoniae pneumonia: a meta-analysis[J]. Medicine (Baltimore), 2021, 100(11): e24894. PMID: 33725960. PMCID: PMC7982158. DOI: 10.1097/MD.0000000000024894.
13 Xing H, Liu X, Li A, et al. Increased peripheral TFH cells and serum interleukin-21 in childhood Mycoplasma pneumoniae pneumonia[J]. J Coll Physicians Surg Pak, 2021, 30(5): 605-607. PMID: 34027881. DOI: 10.29271/jcpsp.2021.05.605.
14 蔡辰, 胡培培, 陆敏, 等. 肺泡灌洗液中细胞因子及细胞学水平与重症肺炎支原体肺炎的相关性[J]. 中华实用儿科临床杂志, 2020, 35(18): 1421-1424. DOI: 10.3760/cma.j.cn101070-20190621-00558.
15 Zhao J, Li Y, Zhang W. The clinical significance of IL-6s and IL-27s in bronchoalveolar lavage fluids from children with Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2020, 20(1): 331. PMID: 32393186. PMCID: PMC7216321. DOI: 10.1186/s12879-020-05017-3.
16 Li J, Rong L, Cui R, et al. Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19[J]. Ann Palliat Med, 2021, 10(4): 3706-3714. PMID: 33615814. DOI: 10.21037/apm-20-2134.
17 Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with coronavirus 2019[J]. Clin Infect Dis, 2020, 71(16): 2174-2179. PMID: 32445579. PMCID: PMC7314209. DOI: 10.1093/cid/ciaa641.
18 关敏, 白雪梅. 几种常见炎症因子在小儿重症肺炎支原体肺炎中的临床意义[J]. 中国小儿急救医学, 2020, 27(5): 371-374. DOI: 10.3760/cma.j.issn.1673-4912.2020.05.012.
19 Ntatsoulis K, Karampitsakos T, Tsitoura E, et al. Commonalities between ARDS, pulmonary fibrosis and COVID-19: the potential of autotaxin as a therapeutic target[J]. Front Immunol, 2021, 12: 687397. PMID: 34671341. PMCID: PMC8522582. DOI: 10.3389/fimmu.2021.687397.
PDF(616 KB)
